首页> 外文期刊>Bratislava Medical Journal >Imaging of deep venous thrombosis using radioactive-labeled tirofiban
【24h】

Imaging of deep venous thrombosis using radioactive-labeled tirofiban

机译:放射性标记的替罗非班对深静脉血栓形成的成像

获取原文
       

摘要

The development of radiolabeled small peptide or peptidomimetic ligands can bind platelets and their specific expressed receptor have been suggested as a new approach to detect the clot location and, more essentially, to determine the age and morphology of the evolving thrombus. This new approach is focused on the use of a series of radiolabeled platelet GPIIb/IIIa receptor antagonists. Tirofiban N-(butylsulfonyl)- 4-O-(4-(4-piperidyl)-L-tyrosine is a non-peptide tyrosine derivate. The aim of the study was to introduce radioactive-labeled tirofiban as a specific imaging agent for acute DVT. The labeling was performed with technetium-99 in the presence of a stannous reducing agent. The labeled preparation showed fast blood clearance in a normal rat model (without induced thrombosis). More than 80 % of the injected dose was eliminated from the circulation in the first hour after injection. Biodistribution and visualization of the labeled molecule was carried out using an experimental model of thrombosis in a male Wistar rat. Planar images were obtained 30 and 60 min after application of 2 × 106 imp/min 99m-technetium-tirofiban in the rat’s tail vein. Sensitivity and specificity were determined using the ratio of ‘left leg positive for DVT’ to ‘right leg negative for DVT’. The obtained ratio was 1.54 after 30 min and 5.04 after 60 min. These values were considered positive in the detection of acute DVT. The high DVT uptake shows that radiolabeled tirofiban in the introduced rat model can be a promising agent for imaging the deep venous thrombosis (Fig. 7, Ref. 25). Keywords: radionuclide labeling, imaging, deep venous thrombosis; 99mTc-tirofiban, rat model. Published online: 28-Oct-2015 Year: 2015, Volume: 116, Issue: 10 Page From: 621, Page To: 626 doi:10.4149/BLL_2015_120 download file ? AEPress s.r.o Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.
机译:放射性标记的小肽或拟肽配体的发展可以结合血小板,其特异性表达的受体已被建议作为一种检测血块位置,更重要的是确定血栓形成的年龄和形态的新方法。这种新方法的重点是使用一系列放射性标记的血小板GPIIb / IIIa受体拮抗剂。替罗非班N-(丁基磺酰基)-4-O-(4-(4-哌啶基)-L-酪氨酸是一种非肽酪氨酸衍生物,该研究的目的是引入放射性标记的替罗非班作为一种特殊的急性成像试剂。 DVT。在亚锡还原剂存在下用tech-99进行标记,标记的制剂在正常大鼠模型中显示出快速的血液清除(没有血栓形成),超过80%的注射剂量从循环中消除在注射后的第一小时内,使用雄性Wistar大鼠血栓形成实验模型对标记分子进行生物分布和可视化,在应用2×106 imp / min 99m-tech后30和60分钟获得平面图像替罗非班在大鼠尾静脉中的敏感性和特异性用“ DVT的左腿阳性”与“ DVT的右腿阴性”之比确定,所得比率为30分钟后1.54和60分钟后5.04。正面ve在急性DVT的检测中。高DVT摄取量表明,在引入的大鼠模型中放射性标记的替罗非班可能是对深静脉血栓形成进行成像的有前途的药物(图7,参考文献25)。关键词:放射性核素标记成像深静脉血栓形成99mTc-替罗非班,大鼠模型。在线发布:2015年10月28日年份:2015,容量:116,发行:10页面从:621,页面到:626 doi:10.4149 / BLL_2015_120下载文件? AEPress s.r.o版权声明:有关复制,存档或以其他方式使用ELiS中的文档的任何许可,请联系AEP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号